Related Experiment Video
Updated: Nov 30, 2025
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.5K
Progress in the Management of Paediatric-Onset Multiple Sclerosis
Aphra Luchesa Smith1, Christina Benetou2, Hayley Bullock3
1University College London Medical School, London WC1E 6DE, UK.
Children (Basel, Switzerland)
|November 13, 2020
Summary
Paediatric-onset multiple sclerosis (POMS) care has improved, with earlier treatment and better monitoring. However, this study couldn't pinpoint specific factors driving these positive changes in POMS patient outcomes.
Area of Science:
- Neuroimmunology
- Paediatric Neurology
Background:
- Paediatric-onset multiple sclerosis (POMS) understanding and treatment have advanced.
- The impact of these advances on patient care and outcomes requires evaluation.
Purpose of the Study:
- To assess how recent advancements in POMS management have influenced patient outcomes.
- To compare patient management and outcomes between two distinct time periods.
Main Methods:
- Retrospective review of 51 POMS patients from two paediatric neuroimmunology centres.
- Comparison of two cohorts: 2007-2010 (n=24) and 2015-2016 (n=27).
- Analysis of demographic, clinical, and neurocognitive data, including treatment timelines and monitoring frequency.
Main Results:
- The later cohort (2015-2016) received disease-modifying therapies sooner after diagnosis (3.5 months vs. 9 months).
- A broader range of treatments and clinical trials were utilized in the later cohort.
- Increased quality of life and neurocognitive monitoring occurred in the later cohort (48% vs. 8% for QoL; 89% vs. 58% for neurocognition).
- Both cohorts showed positive responses to disease-modifying therapies, with reduced annualised relapse rates post-treatment.
Conclusions:
- Over time, POMS patients have benefited from earlier and more diverse treatment options.
- Comprehensive monitoring of quality of life and neurocognitive function has increased.
- Despite observed improvements, the uncontrolled nature of the cohort limits identification of specific determinants for enhanced care in POMS.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
01:24Cystic Fibrosis: Management
321
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
321
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
97
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
97
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
120
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
120
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
128
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
128
01:30Asthma-IV: Nursing Management
3.5K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.5K